Novel transcript, antisense to RBFOX3 (ENSG00000266711)

This target is a predicted long non-coding RNA (lncRNA) transcribed from the RBFOX3 gene locus in the antisense direction[4]. Antisense transcripts such as this are widespread in the genome and are generally non-coding, acting to regulate the expression of their corresponding sense genes through mechanisms such as chromatin modification, RNA masking, transcriptional interference, or potential involvement in RNAi pathways[1][5]. There is no evidence that this specific antisense transcript is a therapeutic target, protein, receptor, transporter, or enzyme. It has not been directly linked to specific diseases, function as a biomarker, or been addressed by drugs in the literature or curated databases. Key clarifications: - This is *not* a therapeutic or druggable target, but a predicted or annotated lncRNA gene[4]. - "Novel transcript, antisense to RBFOX3" is an automatically generated placeholder name based on genome annotation and does not correspond to a characterized, curated gene or protein product. - There is no evidence of misspelling, but as an automated annotation with no known function, detectable protein, or established role in health/disease, this entry is **not suitable as a canonical pharmacological target**[4]. - NATs may influence expression of their sense partner (here, RBFOX3), but specific biochemical or therapeutic significance requires direct experimental evidence, which is currently absent for this entry[1][5].

Other names

antisense to RBFOX3novel transcript, antisense to RBFOX3

Not targeted by drugs; generally, natural antisense transcripts (NATs) can modulate expression of sense genes by RNA masking, transcriptional interference, or RNAi[5][1]